141 related articles for article (PubMed ID: 32577941)
1. Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs.
Hammond S; Wignell A; Cooling P; Barrett DA; Davies P
Intensive Care Med Exp; 2020 Jun; 8(1):25. PubMed ID: 32577941
[TBL] [Abstract][Full Text] [Related]
2. Physico-chemical stability of Plasma-Lyte 148® and Plasma-Lyte 148® + 5% Glucose with eight common intravenous medications.
Dawson R; Wignell A; Cooling P; Barrett D; Vyas H; Davies P
Paediatr Anaesth; 2019 Feb; 29(2):186-192. PubMed ID: 30472805
[TBL] [Abstract][Full Text] [Related]
3. Physical compatibility of ceftriaxone and cefepime in 0.45% sodium chloride, Ringer's lactate solution, and Plasma-Lyte A.
Kelley M; Spooneybarger C; Howard M; Reinert J; Churchwell MD; Baki G
Eur J Hosp Pharm; 2024 Jun; ():. PubMed ID: 38862193
[TBL] [Abstract][Full Text] [Related]
4. Exploring a case of incompatibility in a complex regimen containing Plasma-Lyte 148 in the pediatric intensive care.
Nilsson N; Nguyen V; Nezvalova-Henriksen K; Tho I
Paediatr Anaesth; 2023 Mar; 33(3):211-218. PubMed ID: 36336980
[TBL] [Abstract][Full Text] [Related]
5. Compatibility and stability of ternary admixtures of morphine with haloperidol or midazolam and dexamethasone or methylprednisolone.
Vermeire A; Remon JP
Int J Pharm; 1999 Jan; 177(1):53-67. PubMed ID: 10205603
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the physical compatibility of injectable enrofloxacin with commonly used intravenous fluids and drugs during simulated Y-port administration.
Aghili A; Thomovsky EJ; Johnson PA; Brooks AC; Pierce TJ; Gochenauer AE
Am J Vet Res; 2021 May; 82(5):358-366. PubMed ID: 33904804
[TBL] [Abstract][Full Text] [Related]
7. Compatibility of ketorolac tromethamine injection with common infusion fluids and administration sets.
Floy BJ; Royko CG; Fleitman JS
Am J Hosp Pharm; 1990 May; 47(5):1097-100. PubMed ID: 2337102
[TBL] [Abstract][Full Text] [Related]
8. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
De Basagoiti A; Katsumiti A; Abascal S; Bustinza A; López-Giménez LR; Pascual P; De Miguel M; Campino A
Eur J Pediatr; 2021 Apr; 180(4):1169-1176. PubMed ID: 33128625
[TBL] [Abstract][Full Text] [Related]
9. Physical and Chemical Compatibility of Medications Commonly Used in Critically Ill Patients With Balanced Crystalloids: A Systematic Review.
Buckley CT; Farrar JE; Schleicher M; Stollings JL; Duggal A; Bauer SR
Ann Pharmacother; 2024 Mar; 58(3):322-332. PubMed ID: 37340978
[TBL] [Abstract][Full Text] [Related]
10. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
Wilder AG; Foushee JA; Fox LM; Navalle J; Wright AM; Greer MA
Int J Pharm Compd; 2020; 24(3):238-241. PubMed ID: 32401743
[TBL] [Abstract][Full Text] [Related]
11. The compatibility of a low concentration of hydrocortisone sodium succinate with selected drugs during a simulated Y-site administration.
Semark AJ; Venkatesh K; McWhinney BC; Pretorius C; Roberts JA; Cohen J; Venkatesh B
Crit Care Resusc; 2013 Mar; 15(1):63-6. PubMed ID: 23432505
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of Plasma-Lyte A and 0.9 % sodium chloride in acute pediatric gastroenteritis.
Allen CH; Goldman RD; Bhatt S; Simon HK; Gorelick MH; Spandorfer PR; Spiro DM; Mace SE; Johnson DW; Higginbotham EA; Du H; Smyth BJ; Schermer CR; Goldstein SL
BMC Pediatr; 2016 Aug; 16():117. PubMed ID: 27480410
[TBL] [Abstract][Full Text] [Related]
13. Saline versus Plasma-Lyte A in initial resuscitation of trauma patients: a randomized trial.
Young JB; Utter GH; Schermer CR; Galante JM; Phan HH; Yang Y; Anderson BA; Scherer LA
Ann Surg; 2014 Feb; 259(2):255-62. PubMed ID: 23732264
[TBL] [Abstract][Full Text] [Related]
14. Y-site Injection Physical Compatibility of Remdesivir with Select Intravenous Drugs Used in Palliative Care and for Treating Coronavirus Disease 2019.
Kondo M; Gempei M; Watanabe K; Yoshida M; Tagui N; Fukao S; Sugaya K; Takase H
J Nippon Med Sch; 2023 Nov; 90(5):381-386. PubMed ID: 37271548
[TBL] [Abstract][Full Text] [Related]
15. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Bergquist PA; Manas D; Hunke WA; Reed RA
Am J Health Syst Pharm; 2001 Jul; 58(13):1218-23. PubMed ID: 11449879
[TBL] [Abstract][Full Text] [Related]
16. Compatibility and stability of morphine sulphate and naloxone hydrochloride in 0.9% sodium chloride for injection.
Kistner C; Ensom MH; Decarie D; Lauder G; Carr RR
Can J Hosp Pharm; 2013 May; 66(3):163-70. PubMed ID: 23814283
[TBL] [Abstract][Full Text] [Related]
17. Medication Safety in Intravenous Therapy: A Compatibility Study of Clonidine with Drugs Frequently Used in Intensive Care.
Koller AK; Krebs S; Dörje F
Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33374362
[TBL] [Abstract][Full Text] [Related]
18. Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection.
Riley CM
Am J Hosp Pharm; 1988 Oct; 45(10):2079-91. PubMed ID: 3228079
[TBL] [Abstract][Full Text] [Related]
19. Validation of RP-HPLC method to assess the compatibility of metoclopramide and midazolam intravenous mixture used in patients with cancer.
Sanogo S; Silimbani P; Gaggeri R; Rossi R; Elviri L; Maltoni M; Masini C
Eur J Hosp Pharm; 2019 Nov; 26(6):323-328. PubMed ID: 31798855
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of solutions for the storage of granulocyte colony-stimulating factor-mobilized granulocyte concentrates.
Lightfoot T; Gallelli J; Matsuo K; Kwon SW; Leitman SF; Stroncek DF
Vox Sang; 2001 Feb; 80(2):106-11. PubMed ID: 11378965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
